Loading
Favezelimab is Merck's LAG-3 antibody, tested with pembrolizumab in phase 3 trials in colorectal cancer and classical Hodgkin lymphoma; the colorectal trial did not succeed.
Merck's favezelimab (MK-4280) blocks LAG-3, the second checkpoint validated by relatlimab in melanoma. Coformulated with pembrolizumab as MK-4280A, it entered phase 3 trials in previously treated microsatellite-stable colorectal cancer, where the trial did not meet its overall survival endpoint, and in relapsed classical Hodgkin lymphoma after PD-1 therapy. Registered phase 3 trials remain on ClinicalTrials.gov.
Blocks the LAG-3 checkpoint on exhausted T cells; given with PD-1 blockade to overcome resistance to pembrolizumab alone. Connects to LAG-3.
1.Favezelimab binds LAG-3.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Favezelimab" OR ABSTRACT:"Favezelimab" OR TITLE:"MK-4280" OR ABSTRACT:"MK-4280") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Favezelimab, not a curated reading list.
Shares Merck & Co. (MSD), Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Immune checkpoint inhibitors and the tag pipeline.